<DOC>
	<DOCNO>NCT01082653</DOCNO>
	<brief_summary>A Phase I , single center , prospective , non-randomized , open label , safety/efficacy study infusion autologous bone marrow-derived stem cell , 6 patient Amyotrophic Lateral Sclerosis accord establish criterion ( 1 ) , ( 2 ) moderate severe diagnosis ALS accord World Federation Neurology El Escorial criterion . The primary purpose study evaluate safety infusion procedure , assess absence complication site infusion appearance new neurologic deficit attribute natural progression disease . Secondary outcome include ) neurological evidence trend toward slow decline force vital capacity ( FVC ) ( 3 ) functional rating scale ( ALS-FRS ) score , assess 3-month interval , b ) evidence decline maximum voluntary isometric contraction-arm ( MVIC-arm ) MVIC-grip Z ( 4 ) score c ) patient evaluation treatment effective consider possibility new cell product stem cell infusion . Subjects fulfill inclusion/exclusion criterion sign inform consent undergo aspiration bone marrow iliac crest preparation cellular product . The day infusion , investigational product inject patient 's intrathecal space . After cell infusion patient follow WK 2 , MN 1 , MN 2 , MN 6 long-term followup MN 12 clinic and/or office . Electromyographic ( EMG ) study , Forced vital capacity ( FVC ) , functional rating scale ( FRS ) maximum voluntary isometric contraction-arm ( MVIC-arm ) MVIC-grip Z score use ass status disease ( historical record acceptable do within three month Screening Visit ) 12-month study period cell infusion .</brief_summary>
	<brief_title>Safety/Efficacy Study Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Adult male female subject &gt; 18 year age . 2 . Good understanding protocol willingness consent . 3 . Moderate severe Diagnosis ALS accord World Federation Neurology El Escorial criterion . 4 . Vital capacity least 50 % predict value gender , height age . 5 . More 6 less 36 month evolution disease . 6 . Hematocrit great 30 % prior bone marrow aspiration . 7 . Platelet count great 100 Thousand/uL screening . 8 . INR le equal 1.5 . 1 . Any concurrent illness , affect bone marrow . 2 . Any concomitant medication affect bone marrow . 3 . Previous stem cell therapy . 4 . Any lymphoproliferative disease . 5 . Riluzole 4 week study entry time study . 6 . Hemophiliacs subject bleed disorder . 7 . Known hypersensitivity fetal bovine serum 8 . HIV infection . 9 . Serum creatinine &gt; 3.0 subject hemodialysis . 10 . Skin infection infusion site systemic infection 11 . Current smoker . 12 . Active drug alcohol addiction 13 . Pregnant , plan become pregnant accepted birth control method subject child bear potential . 14 . Subjects breast feeding . 15 . Any condition Principal Investigator considers would render subject unfit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>ALS</keyword>
	<keyword>Lou Gehrig 's Disease</keyword>
</DOC>